StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO – Free Report) in a report issued on Friday morning. The brokerage issued a hold rating on the stock.
Other equities research analysts have also issued reports about the stock. Lake Street Capital started coverage on shares of Ekso Bionics in a report on Monday, June 24th. They set a buy rating and a $2.50 price target for the company. HC Wainwright lifted their price objective on shares of Ekso Bionics from $9.25 to $10.00 and gave the company a buy rating in a research report on Tuesday, April 30th.
Check Out Our Latest Analysis on Ekso Bionics
Ekso Bionics Stock Performance
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last posted its quarterly earnings results on Monday, April 29th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). The company had revenue of $3.76 million for the quarter, compared to analysts’ expectations of $4.99 million. Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. During the same period in the prior year, the business earned ($0.33) EPS. On average, sell-side analysts predict that Ekso Bionics will post -0.43 EPS for the current year.
Hedge Funds Weigh In On Ekso Bionics
An institutional investor recently raised its position in Ekso Bionics stock. Strategic Wealth Investment Group LLC lifted its holdings in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Free Report) by 21.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,950 shares of the company’s stock after purchasing an additional 9,285 shares during the period. Strategic Wealth Investment Group LLC owned about 0.37% of Ekso Bionics worth $130,000 at the end of the most recent reporting period. Institutional investors own 6.42% of the company’s stock.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Read More
- Five stocks we like better than Ekso Bionics
- Using the MarketBeat Dividend Tax Calculator
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Stock Analyst Ratings and Canadian Analyst Ratings
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.